Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIDOSE-2: Low-dose Tocilizumab in COVID-19 Pneumonitis
NCT04479358Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Sep 2020
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by University of Chicago. Started Sep 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04479358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04479358.